3-cyclobutylamino-7-nitro-4H-1,2,4-benzothiadiazine 1,1-dioxide | 201223-82-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻二嗪
• 英文名称: 3-cyclobutylamino-7-nitro-4H-1,2,4-benzothiadiazine 1,1-dioxide
• 英文别名: 3-Cyclobutylamino-7-nitro-4H-1,2,4-benzothiadiazine 1,1-dioxide；3-(Cyclobutylamino)-7-nitro-1lambda~6~,2,4-benzothiadiazine-1,1(4H)-dione；N-cyclobutyl-7-nitro-1,1-dioxo-4H-1λ6,2,4-benzothiadiazin-3-imine
• CAS: 201223-82-7
• 化学式: C₁₁H₁₂N₄O₄S
• 分子量: 296.307
• InChiKey: NZNNWFPVQYZJNH-UHFFFAOYSA-N

物化性质

• 沸点：
  513.3±52.0 °C(Predicted)
• 密度：
  1.80±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  20
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  125
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3-cyclobutylamino-7-nitro-4H-1,2,4-benzothiadiazine 1,1-dioxide 在 palladium on activated charcoal 三氟化硼乙醚 、 氢气 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 生成 7-Chloro-3-cyclobutylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
  参考文献：
  名称：

  Synthesis and evaluation of 7-substituted-3-cyclobutylamino-4H-1,2,4-benzothiadiazine-1,1-dioxide derivatives as KATP channel agonists

  摘要：

  A series of 7-substituted-3-cyclobutylamino-4H-1,2,4-benzothiadiazine-1,1-dioxide derivatives has been synthesized and evaluated as K-ATP channel agonists using the inside-out excised patch clamp technique. The most active compounds were similar to20-fold more potent than diazoxide in opening K-ATP channels. A linear relationship exists between the potency of the compound and the sigma value of the 7-substituent with electron-withdrawing groups exhibiting higher activity. These compounds may be useful in modulating insulin release from pancreatic beta-cells and in diseases associated with hyperinsulinemia. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00617-0
• 作为产物：
  描述：

  环丁基胺 、 3-(1H-imidazol-1-yl)-7-nitro-4H-1,2,4-benzothiadiazine 1,1-dioxide 反应 6.0h， 生成 3-cyclobutylamino-7-nitro-4H-1,2,4-benzothiadiazine 1,1-dioxide
  参考文献：
  名称：

  Synthesis and Biological Effects of New 3-Alkylamino-4<I>H</I>- 1,2,4-Benzothiadiazine 1,1-Dioxides on Insulin-secreting Cells

  摘要：

  DOI：

  10.1211/096089296765556980

文献信息

• Therapeutics for the treatment of glaucoma
  申请人：MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH

  公开号：US10981951B2

  公开（公告）日：2021-04-20

  The present invention provides benzothiadiazine and chroman derivatives and particularly diazoxide and cromakalim derivatives for use in treating glaucoma, retinopathy, treating age related macular degeneration, treating, stabilizing and/or inhibiting blood and lymph vascularization, and reducing intraocular pressure by administering a pharmaceutically effective amount of a prodrug disposed in an ophthalmically acceptable carrier to the eye, wherein the prodrug specifically modulates a KATP channel to reduce an intraocular pressure.

  本发明提供苯并噻二嗪和色苷衍生物，特别是用于治疗青光眼、视网膜病变、治疗年龄相关性黄斑变性、治疗、稳定和/或抑制血液和淋巴血管生成，并通过向眼睛内给予药学有效量的前药，其中前药特异性调节KATP通道以降低眼内压力。
• 1,2,4-benzothiadiazine derivatives, their preparation and use
  申请人：Novo Nordisk AIS

  公开号：US06242443B1

  公开（公告）日：2001-06-05

  1,2,4-Benzothiadiazine derivatives represented by formula wherein D, R1, R2, R3, R4, R5, R12, R13, R14, R15 are defined in the description, composition thereof and methods for preparing the compounds are described. The compounds are useful in the treatment of diseases of the central nervous system, the cardiovascular system, the pulmonary system, the gastrointestinal system and the endocrinological system.

  本文描述了由公式表示的1,2,4-苯并噻二嗪衍生物，其中D、R1、R2、R3、R4、R5、R12、R13、R14、R15在描述中有定义，以及它们的组成和制备方法。这些化合物在治疗中枢神经系统、心血管系统、肺系统、胃肠系统和内分泌系统的疾病中有用。
• NOVEL THERAPEUTICS FOR THE TREATMENT OF GLAUCOMA
  申请人：MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH

  公开号：US20170002040A1

  公开（公告）日：2017-01-05

  The present invention provides benzothiadiazine and chroman derivatives and particularly diazoxide and cromakalim derivatives for use in treating glaucoma, retinopathy, treating age related macular degeneration, treating, stabilizing and/or inhibiting blood and lymph vascularization, and reducing intraocular pressure by administering a pharmaceutically effective amount of a prodrug disposed in an ophthalmically acceptable carrier to the eye, wherein the prodrug specifically modulates a KATP channel to reduce an intraocular pressure.
• THERAPEUTICS FOR THE TREATMENT OF GLAUCOMA
  申请人：Mayo Foundation for Medical Education and Research

  公开号：US20210040148A1

  公开（公告）日：2021-02-11

  The present invention provides benzothiadiazine and chroman derivatives and particularly diazoxide and cromakalim derivatives for use in treating glaucoma, retinopathy, treating age related macular degeneration, treating, stabilizing and/or inhibiting blood and lymph vascularization, and reducing intraocular pressure by administering a pharmaceutically effective amount of a prodrug disposed in an ophthalmically acceptable carrier to the eye, wherein the prodrug specifically modulates a K ATP channel to reduce an intraocular pressure.
• US6242443B1
  申请人：——

  公开号：US6242443B1

  公开（公告）日：2001-06-05